Search results
Exclusive-Drugmakers to raise prices on at least 350 drugs in U.S. in January
Reuters via Yahoo Finance· 1 year agoDrugmakers including Pfizer Inc, GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC and...
The Zacks Analyst Blog Highlights Booz Allen Hamilton, Molson Coors Beverage, Tyson Foods,...
Zacks via Yahoo Finance· 1 month agoFor Immediate Release Chicago, IL – March 14, 2024 – Zacks.com announces the list of stocks featured...
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
Zacks via Yahoo Finance· 2 years agoThe earnings season for the pharma sector began last week, with Johnson & Johnson JNJ reporting...
12 Best Ethical Stocks To Buy Now
Insider Monkey via Yahoo Finance· 2 years agoIn this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to...
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoGlaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven...
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
Zacks via Yahoo Finance· 2 years agoGlaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with...
25 Most Prescribed Medication in the World
Insider Monkey via Yahoo Finance· 11 months agoIn this article, we will be taking a look at the 25 most prescribed medication in the world. To skip our detailed analysis, you can go directly to see...
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
Zacks via Yahoo Finance· 2 years agoGlaxoSmithKline (GSK) closed the most recent trading day at $40.92, moving -1.25% from the previous...
GSK Completes Demerger of Consumer Healthcare Business
Zacks via Yahoo Finance· 2 years agoPost demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer...
GSK: Trials for Respiratory Virus Vaccine "Positive"
Investing.com via Yahoo Finance· 2 years agoBy Scott Kanowsky Investing.com -- GlaxoSmithKline plc (LON:GSK) has announced that its vaccine for respiratory syncytial virus for adults aged 60 and above showed overall efficacy of 82.6%, ...
